Dr. Brown is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 N Wolfe St
Baltimore, MD 21287Phone+1 410-955-6132Fax+1 410-955-8897
Education & Training
- Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2001 - 2004
- Johns Hopkins UniversityResidency, Pediatrics, 1998 - 2001
- Medical University of South CarolinaClass of 1998
Certifications & Licensure
- MD State Medical License 2001 - 2022
Clinical Trials
- Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
- Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Start of enrollment: 2011 Feb 09
- Join now to see all
Publications & Presentations
PubMed
- 205 citationsTreatment of pediatric acute lymphoblastic leukemia.Stacy L. Cooper, Patrick A. Brown
Pediatric Clinics of North America. 2015-02-01 - 41 citationsPhase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol...Maureen M O'Brien, Lingyun Ji, Nirali N Shah, Susan R Rheingold, Deepa Bhojwani
Journal of Clinical Oncology. 2022-03-20 - 61 citationsHow I treat infant leukemiaPatrick A. Brown, Rob Pieters, Andrea Biondi
Blood. 2019-01-17
Abstracts/Posters
- A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...Patrick A. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...Patrick A. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Single Cell Sequencing Reveals Heterogeneity of Gene Expression in KMT2A Rearranged Infant ALL at Relapse Compared to DiagnosisPatrick A. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- Johns Hopkins University: Young Johns Hopkins Children’s Center Patient Shows Superhero Powers in Fight with CancerSeptember 7th, 2021
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/patrick-brown
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: